Pfizer/BioNTech officially applies for an emergency vaccine license for children aged 5-11 in the US

On October 7, pharmaceutical companies Pfizer (USA) and BioNTech (Germany) officially submitted documents to the US Food and Drug Administration (FDA) to apply for a license to vaccinate against COVID-19. of these brands for children 5-11 years old.

Pfizer/BioNTech's COVID-19 vaccine. Photo: AFP
Pfizer/BioNTech's COVID-19 vaccine. Photo: AFP

According to the results of the global clinical trial, Pfizer/BioNTech said their COVID-19 vaccine is safe and produces a strong response with neutralizing antibodies, thereby helping to prevent the SARS-CoV-2 virus from entering. cell. In this trial, children 5-11 years of age received a 2-dose regimen of 10 micrograms, compared with 30 micrograms for the older age groups. The injections are spaced 21 days apart.

Pfizer/BioNTech's COVID-19 vaccine was fully licensed in the US in August, so it would technically be available to children if prescribed by a doctor. However, US authorities have warned that safety data is needed to allow it.

Currently, Pfizer/BioNTech is also testing a vaccine against COVID-19 with infants 6 months to 2 years old and children 2-5 years old. Preliminary data for these groups could be released as soon as the fourth quarter.

Google Tech News

Post a Comment

Previous Post Next Post